Triple-Therapy With PegInterferon alpha-2b + Ribavirin + Boceprevir in Patients With HCV Genotype 3 Who Previously Failed Treatment With PegInterferon alpha + Ribavirin
Phase of Trial: Phase III
Latest Information Update: 08 Jul 2017
At a glance
- Drugs Boceprevir (Primary) ; Peginterferon alfa-2b (Primary) ; Peginterferon; Peginterferon alfa-2b/ribavirin; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms LeeG3
- 28 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Jan 2014 Planned End Date changed from 1 May 2015 to 1 Jan 2015 as reported by ClinicalTrials.gov.
- 21 Jan 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.